Related Experiment Video
Updated: Dec 21, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells
Baris Kucukkaraduman1, Can Turk2, Anna L Fallacara3
1Department of Molecular Biology and Genetics, Bilkent University, Ankara 06800, Turkey.
Abstract:
Melanoma is a highly aggressive cancer with poor prognosis. Although more than 80% of melanomas harbor an activating mutation in genes within the MAPK pathway, which are mutually exclusive, usefulness of therapies targeting MAPK pathway are impeded by innate and/or acquired resistance in most patients. In this study, using melanoma cells, we report the efficacy of a recently developed pyrazolo[3,4-d]pyrimidine derived c-Src inhibitor 10a and identify a molecular signature which is predictive of 10a chemosensitivity. We show that the expression of TMED7, PLOD2, XRCC5, and NSUN5 are candidate biomarkers for 10a sensitivity. Although an undifferentiated/mesenchymal/invasive status of melanoma cells is associated with resistance to 10a, we show here for the first time that melanoma cells can be sensitized to 10a via treatment with valproic acid, a histone deacetylase inhibitor.
Insights
This study reveals a new c-Src inhibitor, 10a, for melanoma treatment. It identifies biomarkers for sensitivity and shows valproic acid can overcome resistance, improving melanoma therapy options.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Melanoma is an aggressive cancer with poor prognosis.
- MAPK pathway mutations are common but therapies face resistance.
- Targeting c-Src is a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy of pyrazolo[3,4-d]pyrimidine derived c-Src inhibitor 10a in melanoma.
- To identify molecular biomarkers predictive of 10a sensitivity.
- To investigate methods to overcome resistance to 10a.
Main Methods:
- Utilized melanoma cell lines.
- Assessed the efficacy of c-Src inhibitor 10a.
- Analyzed gene expression for biomarker identification.
- Investigated the effect of valproic acid on 10a sensitivity.
Main Results:
- Inhibitor 10a demonstrated efficacy in melanoma cells.
- TMED7, PLOD2, XRCC5, and NSUN5 expression levels predict 10a sensitivity.
- Undifferentiated/mesenchymal melanoma cells showed resistance to 10a.
- Valproic acid sensitized melanoma cells to 10a.
Conclusions:
- c-Src inhibitor 10a is a promising agent for melanoma treatment.
- A molecular signature (TMED7, PLOD2, XRCC5, NSUN5) can predict response to 10a.
- Valproic acid can overcome 10a resistance, offering a novel therapeutic approach.
